Drugmakers rally after Pfizer agreement as Most Favored Nation plans still loom over sector.
Get this delivered to your inbox, and more info about our products and services.
Markets failed to rally despite what analysts said was a clear win for the European pharmaceutical sector in a trade update…
A number of global pharma firms have pulled or paused U.K. investment plans amid waning government support and drug pricing talks.
A fresh ultimatum demanding "binding commitments" to lower U.S. drug prices sent pharma firms scrambling Friday.
Pfizer's deal with Trump was a relief to the pharma industry, signaling that drugmakers could strike similar agreements that…
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD…
Pharma giants are navigating President Trump's demands to bring U.S. drug prices in line with other developed nations.
